BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 29292876)

  • 1. Correlation of Bone Mineral Density on Quality of Life in Patients with Osteogenesis Imperfecta during Treatment with Denosumab.
    Hoyer-Kuhn H; Stark C; Franklin J; Schoenau E; Semler O
    Pediatr Endocrinol Rev; 2017 Nov; 15(Suppl 1):123-129. PubMed ID: 29292876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized treatment with denosumab in children with osteogenesis imperfecta - follow up of a trial cohort.
    Hoyer-Kuhn H; Rehberg M; Netzer C; Schoenau E; Semler O
    Orphanet J Rare Dis; 2019 Sep; 14(1):219. PubMed ID: 31533771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial.
    Hoyer-Kuhn H; Franklin J; Allo G; Kron M; Netzer C; Eysel P; Hero B; Schoenau E; Semler O
    J Musculoskelet Neuronal Interact; 2016 Mar; 16(1):24-32. PubMed ID: 26944820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TBS as a Tool to Differentiate the Impact of Antiresorptives onCortical and Trabecular Bone in Children With OsteogenesisImperfecta.
    Rehberg M; Winzenrieth R; Hoyer-Kuhn H; Duran I; Schoenau E; Semler O
    J Clin Densitom; 2019; 22(2):229-235. PubMed ID: 30309730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two years' experience with denosumab for children with osteogenesis imperfecta type VI.
    Hoyer-Kuhn H; Netzer C; Koerber F; Schoenau E; Semler O
    Orphanet J Rare Dis; 2014 Sep; 9():145. PubMed ID: 25257953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up in osteogenesis imperfecta type VI.
    Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
    Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Denosumab for Osteoporosis in Three Female Patients with Osteogenesis Imperfecta.
    Uehara M; Nakamura Y; Takahashi J; Kamimura M; Ikegami S; Suzuki T; Uchiyama S; Yamaguchi T; Kosho T; Kato H
    Tohoku J Exp Med; 2017 Jun; 242(2):115-120. PubMed ID: 28626166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI.
    Trejo P; Rauch F; Ward L
    J Musculoskelet Neuronal Interact; 2018 Mar; 18(1):76-80. PubMed ID: 29504582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy with pamidronate in children with osteogenesis imperfecta.
    Marginean O; Tamasanu RC; Mang N; Mozos I; Brad GF
    Drug Des Devel Ther; 2017; 11():2507-2515. PubMed ID: 28894358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
    Feehan AG; Zacharin MR; Lim AS; Simm PJ
    Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
    Boskey AL; Marino J; Spevak L; Pleshko N; Doty S; Carter EM; Raggio CL
    Clin Orthop Relat Res; 2015 Aug; 473(8):2587-98. PubMed ID: 25903941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteogenesis imperfecta - A clinical update.
    Tournis S; Dede AD
    Metabolism; 2018 Mar; 80():27-37. PubMed ID: 28625337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
    Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
    Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI.
    Semler O; Netzer C; Hoyer-Kuhn H; Becker J; Eysel P; Schoenau E
    J Musculoskelet Neuronal Interact; 2012 Sep; 12(3):183-8. PubMed ID: 22947550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteogenesis imperfecta: from diagnosis and multidisciplinary treatment to future perspectives.
    Bregou Bourgeois A; Aubry-Rozier B; Bonafé L; Laurent-Applegate L; Pioletti DP; Zambelli PY
    Swiss Med Wkly; 2016; 146():w14322. PubMed ID: 27346233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteogenesis Imperfecta Type VI in Individuals from Northern Canada.
    Ward L; Bardai G; Moffatt P; Al-Jallad H; Trejo P; Glorieux FH; Rauch F
    Calcif Tissue Int; 2016 Jun; 98(6):566-72. PubMed ID: 26815784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab: an Emerging Therapy in Pediatric Bone Disorders.
    Boyce AM
    Curr Osteoporos Rep; 2017 Aug; 15(4):283-292. PubMed ID: 28643220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of the effect of denosumab on children with osteogenesis imperfecta showed inconsistent findings.
    Li G; Jin Y; Levine MAH; Hoyer-Kuhn H; Ward L; Adachi JD
    Acta Paediatr; 2018 Mar; 107(3):534-537. PubMed ID: 29154388
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.